Evidence map›Paper›PMID 41922144›Full record

Observational studyESMO open2026

Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.

T Matsubara, T Sakamoto, T Takahama, T Yokoyama, I Yoshino, H Akamatsu, M Yamaguchi, J Baba, T Tokito, M Tachihara and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

T MatsubaraDepartment of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
T SakamotoDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.
T TakahamaDepartment of Medical Oncology, Kindai University, Higashiosaka, Osaka, Okayama, Japan. Electronic address: takahama_t@med.kindai.ac.jp.
T YokoyamaDepartment of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
I YoshinoDepartment of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
H AkamatsuInternal Medicine III, Wakayama Medical University, Kimiidera, Wakayama, Japan.
M YamaguchiDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
J BabaDepartment of Internal Medicine, Niigata Cancer Center, Kawagishi-cho, Niigata, Japan.
T TokitoDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University Hospital, Kurume, Fukuoka, Japan.
M TachiharaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Y SatoDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
T TakenakaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
K SugioDepartment of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Oita, Japan.
M MoriDepartment of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.
T TakeuchiXcoo, Inc., Hongo, Tokyo, Japan.
K OkazukaTakeda Pharmaceutical Company Limited, Nihonbashi-Honcho, Tokyo, Japan.
H KenmotsuDivision of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan.
J FujimotoClinical Research Center in Hiroshima, Hiroshima University Hospital, Hiroshima, Japan.
M ShimokawaDepartment of Biostatistics, Yamaguchi University, Yoshida, Yamaguchi, Japan.
N YamamotoDepartment of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
K NakagawaDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to investigate the status of biomarker testing and prognosis in patients with post-operative recurrent non-small-cell lung cancer (NSCLC). PATIENTS AND

methodsThis retrospective multicenter study included 1500 patients with advanced or recurrent NSCLC from 29 institutions between July 2020 and June 2021. A post-operative recurrence subgroup analysis was carried out on 229 patients. The main focus was on the testing rate for biomarkers, including multigene testing. Survival analyses were also conducted.

resultsThe median age of the study cohort was 74 years (range 40-92 years). Of the patients, 46.5% had stage I NSCLC, and 67% had adenocarcinoma. Median time from surgery to recurrence was 511 days, and 169 patients had distant metastases; 23% of the patients underwent rebiopsy to confirm recurrence. Multigene testing was conducted in 43.7% of the patients, and single-gene testing in 56.8%. Multigene testing was more frequent in cases with distant metastases (47%) compared with local recurrences (35%). No significant difference in testing success was observed between the resected preserved specimens and the rebiopsied recurrent specimens. Multigene testing was less likely if recurrence occurred >3 years after surgery. Post-operative recurrent patients had better overall survival than advanced-stage patients in both the overall cohort and the driver-positive subgroup.

conclusionsThe rate of multigene testing in post-operative recurrent NSCLC cases was low despite the availability of sufficient surgical specimens. The further widespread adoption of multigene testing is one of the most critical challenges for improving resected patient outcomes along with recent advances in perioperative personalized medicine.

Indexed as

Carcinoma, Non-Small-Cell LungGenetic TestingLung NeoplasmsNeoplasm Recurrence, LocalAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, Tumorbiomarkerdriver mutationmultigene testingnon-small-cell lung cancerrecurrencethoracic surgery

Identifiers

PMID41922144
PMCPMC13068564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.